Cisapride 20 mg b.d. for preventing symptoms of GERD induced by a provocative meal
- 1 June 1999
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 13 (6) , 787-794
- https://doi.org/10.1046/j.1365-2036.1999.00525.x
Abstract
: Cisapride is a substituted piperidinyl benzamide indicated for the symptomatic treatment of patients with nocturnal heartburn due to gastro-oesophageal reflux disease (GERD). The currently recommended dosing regimen for cisapride is 10 mg q.d.s., but the elimination half-life of 8–10 h supports b.d. dosing with 20 mg. : This multicentre, randomized, double-blind, placebo-controlled trial was undertaken to determine the efficacy and safety of cisapride 20 mg b.d. dosing in reducing or preventing heartburn and other meal-related symptoms after challenge with a provocative fatty meal. In phase 1 of the study, 137 patients with at least a 3-month history of symptoms suggestive of GERD and at least five episodes of GERD on 7-day diary were eligible to receive single-blind treatment with placebo for 7 (range ± 3) days and then ingested a provocative meal. One hundred and twenty-two patients (45 men and 77 women, 22–65 years of age) who experienced heartburn during the 3 h after ingestion of the meal qualified for the double-blind phase of the study and were randomly assigned to either cisapride 20 mg or matching placebo b.d. for 7 (±3) days. At the end of this period, 118 patients again ate a fatty meal and were assessed for symptoms of GERD. : Heartburn was prevented in a significantly higher percentage of cisapride-treated patients (40%; 24 out of 60) than placebo-treated patients (21%; 12 out of 58) after the repeat provocative meal at the end of the double-blind phase (P = 0.017). Cisapride was also significantly more effective in reducing the severity of postprandial heartburn, belching, and regurgitation (P < 0.05). Twice-daily dosing with cisapride 20 mg was well tolerated; the number of cisapride- and placebo-treated patients who experienced at least one adverse event was similar (31% and 22%, respectively). The most common adverse events were diarrhoea (cisapride, 18%; placebo, 0%) and rhinitis (cisapride, 2%; placebo, 5%). : These results demonstrate that cisapride 20 mg b.d. is effective in preventing or reducing symptoms of heartburn in patients who developed heartburn after ingesting a provocative fatty meal. Cisapride was also effective in reducing the severity of heartburn-related symptoms such as belching and regurgitation.Keywords
This publication has 14 references indexed in Scilit:
- Efficacy of cisapride therapy in functional dyspepsiaAlimentary Pharmacology & Therapeutics, 2007
- A double-blind, placebo-controlled study of the effectiveness and safety of nizatidine in the prevention of postprandial heartburnArchives of internal medicine (1960), 1997
- Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapyGastroenterology, 1997
- Factors affecting dose selection and outcome of cisapride treatment for dyspepsia in primary careAlimentary Pharmacology & Therapeutics, 1996
- Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double‐blind comparison with ranitidineAlimentary Pharmacology & Therapeutics, 1993
- Effect of cisapride on relapse of esophagitisDigestive Diseases and Sciences, 1993
- Factors Affecting Short- and Long-Term Outcome of a Short Therapeutic Trial with Cisapride in Dyspeptic Patients: General DiscussionScandinavian Journal of Gastroenterology, 1993
- Effect of Cisapride on Relapse of Reflux Oesophagitis, Healed with an Antisecretory DrugScandinavian Journal of Gastroenterology, 1992
- How often is medication taken as prescribed? A novel assessment techniqueJAMA, 1989
- CisaprideDrugs, 1988